表达CRT-E2融合蛋白肿瘤疫苗诱导特异性抗肿瘤免疫应答

Vaccination of mice with B16 cells expressing the CRT-E2 fusion protein induces anti-tumor immune responses

目的:探讨表达钙网蛋白(Calreticulin,CRT)和HPVE2融合蛋白的肿瘤疫苗在小鼠体内诱导的抗肿瘤免疫应答。方法:转染重组质粒得到高表达CRT、E2和CRT-E2融合蛋白的肿瘤细胞,作为肿瘤疫苗隔周两次腹腔注射免疫小鼠,17天后观察成瘤率,检测NK细胞杀伤活性、特异性T细胞增殖能力、CTL活性以及脾淋巴细胞分泌IFN-γ水平,并观察荷瘤小鼠生存期。结果:高表达CRT-E2融合蛋白肿瘤疫苗免疫小鼠后,其成瘤率明显低于其他实验组,NK细胞杀伤活性、特异性T细胞增殖能力、CTL活性和脾淋巴细胞分泌IFN-γ水平均显著高于其它实验组(P<0.01),生存期也明显延长(P<0.01)。结论:小鼠体内实验显示,表达CRT-E2融合蛋白肿瘤疫苗能够诱导特异性CD8+T细胞免疫应答和NK细胞活性,显著抑制了肿瘤生长。

Objective：To study the anti-tumor effects by vaccination of mice with murine melanoma B16 cells expressing calreticulin （CRT） and Human papillomavirus 16 E2 fusion protein. Methods： Mice were inoculated with B16 cells expressing CRT, E2, or CRT-E2 by intraperitoneal injection. The inoculation was repeated after one week. The activity of CTLs and NK cells, the proliferation of T cells and the amount of IFN-γ secreted by spleen lymphocytes were analysed. Results：The activity of CTLs and NK ceils, and the amount of IFN-γ secreted by spleen hnyphocytes from mice vaccinated with CRT-E2 fusion protein were significantly higher than those of the other groups（ P 〈 0.01）. Conclusion：Vaccination of mice with melanoma B16 cells expressing CRT-E2 fusion protein can induce the activation of CTLs and NK cells, whereby to stimulate anti-tumor effects.